3rd Quarter - Amendment

NATIONAL BREAST CANCER COALITION FUND for NATIONAL BREAST CANCER COALITION FUND

Firm
Client
Income
—
Expenses
$68,162
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report Oct 19, 2015 $68,162 Replaced
3rd Quarter - Amendment (this page) Apr 13, 2018 $68,162 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

Funding for the DOD peer-reviewed Breast Cancer Research Program.

LobbyistCovered position, as disclosed
IRENE BUENO New —
LISA GERMAN FOSTER New —
MARGARITA VALDEZ New —
FRANCES M VISCO —

Contacted: Defense Advanced Research Projects Agency (DARPA); Centers For Disease Control & Prevention (CDC); White House Office; Natl Institutes of Health (NIH); SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Defense, Dept of (DOD); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Health Issues HCR

Funding for the DOD peer-reviewed Breast Cancer Research Program; Guaranteed Access to Quality Care for All; Medicaid Breast and Cervical Cancer Treatment Program; Health Care Reform; Issues and legislation related to the Breast Cancer Deadline 2020 goal of knowing how to end breast cancer by January 1, 2020.

LobbyistCovered position, as disclosed
IRENE BUENO New —
LISA GERMAN FOSTER —
MARGARITA VALDEZ New —
FRANCES M VISCO —

Contacted: Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); White House Office; Defense Advanced Research Projects Agency (DARPA); Defense, Dept of (DOD)

Medical/Disease Research/Clinical Labs MED

Funding for the DOD peer-reviewed Breast Cancer Research Program; Issues and legislation related to the Breast Cancer Deadline 2020 goal of knowing how to end breast cancer by January 1, 2020.

LobbyistCovered position, as disclosed
IRENE BUENO —
LISA GERMAN FOSTER —
MARGARITA VALDEZ New —
FRANCES M VISCO —

Contacted: White House Office; Centers For Disease Control & Prevention (CDC); Defense Advanced Research Projects Agency (DARPA); HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD); Food & Drug Administration (FDA); Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.